Potential retinal disease treatments to be presented at ARVO

Preclinical results for two new compounds (Sirion) that may be used for the treatment of retinal diseases will be presented during the 2008 annual meeting of the Association for Research in Vision and Ophthalmology.

Related Videos
Related Content

Study examines connection between retinoblastoma and maternal smoking

March 23rd 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Visus Therapeutics completes enrollment in BRIO-I Phase 3 clinical trial of Brimochol PF for the treatment of presbyopia

March 22nd 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Evidence-based debates and discussions at COPHy 2023

March 21st 2023

The evolution of corneal transplantation surgery

March 21st 2023

Study examines connection between retinoblastoma and maternal smoking

March 23rd 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Visus Therapeutics completes enrollment in BRIO-I Phase 3 clinical trial of Brimochol PF for the treatment of presbyopia

March 22nd 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Evidence-based debates and discussions at COPHy 2023

March 21st 2023

The evolution of corneal transplantation surgery

March 21st 2023

Study examines connection between retinoblastoma and maternal smoking

March 23rd 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Visus Therapeutics completes enrollment in BRIO-I Phase 3 clinical trial of Brimochol PF for the treatment of presbyopia

March 22nd 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Evidence-based debates and discussions at COPHy 2023

March 21st 2023

The evolution of corneal transplantation surgery

March 21st 2023
© 2023 MJH Life Sciences

All rights reserved.